- **Klotho Neurosciences** announced that its **Letter of Intent with Turn Biotechnologies was allowed to expire** by both parties.  **[1907223_20251007LA92782:0]** 
- The company's Board of Directors determined that the **proposed transaction did not align with its long-term strategic plan**.  **[1907223_20251007LA92782:0]** 
- Klotho will now **focus its resources on advancing its Klotho anti-aging protein research pipeline** and developing treatments.  **[1907223_20251007LA92782:0]** 
- The company highlights the **longevity medicine market as a fast-growing sector**, with the global aging population projected to reach 2.1 billion by 2050 and healthcare costs to exceed $47 trillion by 2030.  **[1907223_20251007LA92782:0]**

Klotho Neurosciences Announces Expiration of Letter of Intent

- **Klotho Neurosciences (KLTO)** has signed a Letter of Intent (LOI) to acquire select assets from **Turn Biotechnologies**, including its ERA platform and eTurna RNA delivery system.  **[1907223_20250930LA86133:0]** 
- The transaction includes a signed out-licensing and co-development partnership with a South Korean pharmaceutical company, valued at up to **$300 million**.  **[1907223_20250930LA86133:0]** 
- This acquisition is intended to position Klotho as a leader in longevity therapeutics, expanding its mission and therapeutic reach, with plans for rebranding and integrating key Turn personnel.  **[1907223_20250930LA86133:0]**